Rodman & Renshaw began coverage on shares of Mural Oncology (NASDAQ:MURA – Free Report) in a research note published on Friday morning, MarketBeat reports. The brokerage issued a buy rating and a $15.00 target price on the stock.
Separately, Morgan Stanley assumed coverage on Mural Oncology in a research note on Thursday, April 4th. They issued an overweight rating and a $13.00 price objective for the company.
View Our Latest Stock Analysis on MURA
Mural Oncology Stock Down 1.0 %
Mural Oncology (NASDAQ:MURA – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($1.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.82. Sell-side analysts forecast that Mural Oncology will post -7.54 EPS for the current year.
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Further Reading
- Five stocks we like better than Mural Oncology
- Market Cap Calculator: How to Calculate Market Cap
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Why Are Stock Sectors Important to Successful Investing?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Breakout Stocks: What They Are and How to Identify Them
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.